Curcumin, a natural bioactive polyphenol, has been widely investigated as a conventional medicine for centuries. Over the past
two decades, major pre-clinical and clinical trials have demonstrated its safe therapeutic profile but clinical translation has been hampered
due to rapid degradation, poor water solubility, bioavailability and pharmaco-kinetics. To overcome such translational issues, many laboratories
have focused on developing curcumin nanoformulations for cancer therapeutics. In this review, we discuss the evolution of curcumin
nanomedicine in cancer therapeutics, the possible interactions between the surface of curcumin nanoparticles and plasma proteins,
the role of nanoparticle-protein complex architecture parameters, and the rational design of clinically useful curcumin nanoformulations.
Considering all the biologically relevant phenomena, curcumin nanoformulations can be developed as a new neutraceutical or pharmaceutical
Keywords: Polyphenol, drug delivery, nanomedicine, cancer therapeutics, bioavailability, protein corona.
Rights & PermissionsPrintExport